Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed.
Age
60–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women between the ages of 60 and 90 years.
Diagnosis of a geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration.
Best Corrected Visual Acuity (BCVA) of 20/80 or better in the study eye
You may not be if
Evidence of ocular disease other than geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration in the study eye.
History or diagnosis of exudative (wet) Age-Related Macular Degeneration, with subretinal or choroidal neovascular lesions in the study eye.
Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous, immune, or gastrointestinal system
Clareo Health | Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
